MIR155HG^Δexon3 human T cells protects from acute GVHD in a xenogeneic model of disease. Xenogeneic GVHD transplants were performed as described in methods. NSG mice were injected with (A) 5 × 10⁶ (n = 3 per cohort) and (B) 10 × 10⁶ MIR155HG^Δexon3 or NT human T cells (n = 5 per cohort). Survival curves (left) and acute GVHD clinical scores (right). Data combined from 2 independent donors, ∗P < .05, ∗∗P < .01, ∗∗∗P < .001. (C) Representative images of NT (left) and MIR155HG^Δexon3 (right) recipient mice when the GVHD scores reached ≥4 and mice met euthanization criteria in the NT cohort. (D) Hematoxylin and eosin staining of liver (top) and skin (bottom) sections from mice receiving MIR155HG^Δexon3 (right) or NT T cells (left). (E) Pathology scores for liver and skin from MIR155HG^Δexon3 and NT-recipient mice at time of euthanasia (∗P < .05).